EMA to review Krystexxa for gout

EMA accepted for review an MAA from Savient Pharmaceuticals Inc. (NASDAQ:SVNT) for Krystexxa pegloticase to treat chronic gout in patients refractory to conventional therapy. The pegylated urate oxida...